Literature DB >> 17387610

Cardiac hypertrophy induced by sustained beta-adrenoreceptor activation: pathophysiological aspects.

Oleg E Osadchii1.   

Abstract

Cardiac hypertrophy is promoted by adrenergic over-activation and represents an independent risk factor for cardiovascular morbidity and mortality. The basic knowledge about mechanisms by which sustained adrenergic activation promotes myocardial growth, as well as understanding how structural changes in hypertrophied myocardium could affect myocardial function has been acquired from studies using an animal model of chronic systemic beta-adrenoreceptor agonist administration. Sustained beta-adrenoreceptor activation was shown to enhance the synthesis of myocardial proteins, an effect mediated via stimulation of myocardial growth factors, up-regulation of nuclear proto-oncogenes, induction of cardiac oxidative stress, as well as activation of mitogen-activated protein kinases and phosphatidylinositol 3-kinase. Sustained beta-adrenoreceptor activation contributes to impaired cardiac autonomic regulation as evidenced by blunted parasympathetically-mediated cardiovascular reflexes as well as abnormal storage of myocardial catecholamines. Catecholamine-induced cardiac hypertrophy is associated with reduced contractile responses to adrenergic agonists, an effect attributed to downregulation of myocardial beta-adrenoreceptors, uncoupling of beta-adrenoreceptors and adenylate cyclase, as well as modifications of downstream cAMP-mediated signaling. In compensated cardiac hypertrophy, these changes are associated with preserved or even enhanced basal ventricular systolic function due to increased sarcoplasmic reticulum Ca(2+) content and Ca(2+)-induced sarcoplasmic reticulum Ca(2+) release. The increased availability of Ca(2+) to maintain cardiomyocyte contraction is attributed to prolongation of the action potential due to inhibition of the transient outward potassium current as well as stimulation of the reverse mode of the Na(+)-Ca(2+) exchange. Further progression of cardiac hypertrophy towards heart failure is due to abnormalities in Ca(2+) handling, necrotic myocardial injury, and increased myocardial stiffness due to interstitial fibrosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17387610     DOI: 10.1007/s10741-007-9007-4

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.654


  252 in total

1.  Increase in type I adenosine 3',5'-monophosphate-dependent protein kinase during isoproterenol-induced cardiac hypertrophy.

Authors:  C V Byus; J M Chubb; R J Huxtable; D H Russell
Journal:  Biochem Biophys Res Commun       Date:  1976-12-06       Impact factor: 3.575

2.  Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy.

Authors:  J Suzuki; I Ohno; J Nawata; S Miura; J Ikeda; K Shirato
Journal:  J Cardiovasc Pharmacol       Date:  1999-11       Impact factor: 3.105

3.  Increased responsiveness of left ventricular apical myocardium to adrenergic stimuli.

Authors:  H Mori; S Ishikawa; S Kojima; J Hayashi; Y Watanabe; J I Hoffman; H Okino
Journal:  Cardiovasc Res       Date:  1993-02       Impact factor: 10.787

4.  Quinidine pharmacodynamics in normal and isoproterenol-induced hypertrophied blood-perfused working rabbit hearts.

Authors:  A M Gillis; H J Mathison; C Patel; W M Lester
Journal:  J Cardiovasc Pharmacol       Date:  1996-06       Impact factor: 3.105

5.  Differential regulation of beta-1 and beta-2 adrenoceptors in guinea pig atrioventricular conducting system after chronic (-)-isoproterenol infusion.

Authors:  P Molenaar; J J Smolich; F D Russell; L R McMartin; R J Summers
Journal:  J Pharmacol Exp Ther       Date:  1990-10       Impact factor: 4.030

6.  Direct effect of beta-adrenergic stimulation on renin release by the rat kidney slice in vitro.

Authors:  M H Weinberger; W Aoi; D P Henry
Journal:  Circ Res       Date:  1975-09       Impact factor: 17.367

7.  Effects of norepinephrine on expression of IGF-1/IGF-1R and SERCA2 in rat heart.

Authors:  X Sun; Y C Ng
Journal:  Cardiovasc Res       Date:  1998-01       Impact factor: 10.787

8.  Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts.

Authors:  W Schorb; G W Booz; D E Dostal; K M Conrad; K C Chang; K M Baker
Journal:  Circ Res       Date:  1993-06       Impact factor: 17.367

9.  Role of phosphatidylinositol 3-kinase activation in the hypertrophic growth of adult ventricular cardiomyocytes.

Authors:  K D Schlüter; Y Goldberg; G Taimor; M Schäfer; H M Piper
Journal:  Cardiovasc Res       Date:  1998-10       Impact factor: 10.787

10.  Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy.

Authors:  M Nagano; J Higaki; F Nakamura; K Higashimori; N Nagano; H Mikami; T Ogihara
Journal:  Hypertension       Date:  1992-06       Impact factor: 10.190

View more
  61 in total

1.  Fibroblast Growth Factor 2 Mediates Isoproterenol-induced Cardiac Hypertrophy through Activation of the Extracellular Regulated Kinase.

Authors:  Stacey L House; Brian E House; Betty Glascock; Thomas Kimball; Eyad Nusayr; Jo El J Schultz; Thomas Doetschman
Journal:  Mol Cell Pharmacol       Date:  2010

2.  Chronic sympathetic activation promotes downregulation of β-adrenoceptor-mediated effects in the guinea pig heart independently of structural remodeling and systolic dysfunction.

Authors:  Ewa Soltysinska; Stefanie Thiele; Søren Peter Olesen; Oleg E Osadchii
Journal:  Pflugers Arch       Date:  2011-08-03       Impact factor: 3.657

Review 3.  Cyclic AMP synthesis and hydrolysis in the normal and failing heart.

Authors:  Aziz Guellich; Hind Mehel; Rodolphe Fischmeister
Journal:  Pflugers Arch       Date:  2014-04-24       Impact factor: 3.657

4.  Exercise training inhibits inflammatory cytokines and more than prevents myocardial dysfunction in rats with sustained beta-adrenergic hyperactivity.

Authors:  Andrey J Serra; Marília H H Santos; Danilo S Bocalini; Ednei L Antônio; Rozeli F Levy; Alexandra A Santos; Maria L Higuchi; José A Silva; Flávio C Magalhães; Valério G Baraúna; José E Krieger; Paulo J F Tucci
Journal:  J Physiol       Date:  2010-05-04       Impact factor: 5.182

Review 5.  AKAP phosphatase complexes in the heart.

Authors:  John M Redden; Kimberly L Dodge-Kafka
Journal:  J Cardiovasc Pharmacol       Date:  2011-10       Impact factor: 3.105

6.  Early manifestation of alteration in cardiac function in dystrophin deficient mdx mouse using 3D CMR tagging.

Authors:  Wei Li; Wei Liu; Jia Zhong; Xin Yu
Journal:  J Cardiovasc Magn Reson       Date:  2009-10-22       Impact factor: 5.364

7.  Deficiency of iNOS Does Not Prevent Isoproterenol-induced Cardiac Hypertrophy in Mice.

Authors:  Hye-Na Cha; Geu-Ru Hong; Yong-Woon Kim; Jong-Yeon Kim; Jin-Myoung Dan; So-Young Park
Journal:  Korean J Physiol Pharmacol       Date:  2009-06-30       Impact factor: 2.016

8.  Simultaneous transforming growth factor beta-tumor necrosis factor activation and cross-talk cause aberrant remodeling response and myocardial fibrosis in Timp3-deficient heart.

Authors:  Zamaneh Kassiri; Virginie Defamie; Mehrdad Hariri; Gavin Y Oudit; Shalini Anthwal; Fayez Dawood; Peter Liu; Rama Khokha
Journal:  J Biol Chem       Date:  2009-07-22       Impact factor: 5.157

9.  Analysis of GNAS1 and PRKAR1A gene mutations in human cardiac myxomas not associated with multiple endocrine disorders.

Authors:  G Mantovani; S Bondioni; S Corbetta; L Menicanti; B Rubino; E Peverelli; P Labarile; C Dall'Asta; B Ambrosi; P Beck-Peccoz; A G Lania; A Spada
Journal:  J Endocrinol Invest       Date:  2009-04-29       Impact factor: 4.256

10.  Cardiovascular response to beta-adrenergic blockade or activation in 23 inbred mouse strains.

Authors:  Corinne Berthonneche; Bastian Peter; Fanny Schüpfer; Pamela Hayoz; Zoltán Kutalik; Hugues Abriel; Thierry Pedrazzini; Jacques S Beckmann; Sven Bergmann; Fabienne Maurer
Journal:  PLoS One       Date:  2009-08-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.